18 results
8-K
EX-99.2
GOSS
Gossamer Bio Inc
14 May 19
Gossamer Bio Announces First Quarter 2019 Financial Results
7:31am
antagonism is believed to reduce airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment GB001
Japanese Phase 2 Study … strategies to help overcome resistance to T-cell activating therapies in the clinic GB1275 mediated CD11b modulation Impacts myeloid cell recruitment
8-K
EX-99.2
GOSS
Gossamer Bio Inc
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
of the DP2 receptor DP2 antagonism has shown the potential to inhibit recruitment of airway eosinophils and reduce airway inflammation GB001 exhibits
8-K
EX-10.1
GOSS
Gossamer Bio Inc
27 Nov 23
Departure of Directors or Certain Officers
4:01pm
satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation
S-1
EX-10.5
GOSS
Gossamer Bio Inc
21 Dec 18
IPO registration
4:39pm
or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources
S-1/A
EX-10.5
GOSS
Gossamer Bio Inc
23 Jan 19
IPO registration (amended)
4:39pm
models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance
PRE 14A
x52 ed7o2q2h
17 Apr 23
Preliminary proxy
4:01pm
S-1/A
azq0s z86c
23 Jan 19
IPO registration (amended)
4:39pm
424B4
vd6o5zxriaex3e2xqgq
8 Feb 19
Prospectus supplement with pricing info
4:40pm
S-1
seylvo6a
21 Dec 18
IPO registration
4:39pm
DRS
mcy8vd
11 Oct 18
Draft registration statement
12:00am
DRS/A
86c7frm xr6a3epfklks
29 Nov 18
Draft registration statement (amended)
12:00am
10-K
ljwv2i57kpkod5cg
22 Mar 19
Annual report
4:45pm
- Prev
- 1
- Next